冠状动脉粥样硬化性心脏病的治疗新方向——PCSK9抑制剂  

New Direction of Coronary Atherosclerotic Heart DiseaseTreatment—PCSK9 Inhibitors

作　　者：刘杨[1,2] 陈明 LIU Yang;CHEN Ming(Department of Cardiology,The First Affiliated Hospital of Chongqing Medical University,Chongqing 400016,China;Yunyang County People s Hospital,Chongqing 404500,China)

机构地区：[1]重庆医科大学附属第一医院心内科,重庆400016 [2]云阳县人民医院,重庆404500

出　　处：《心血管病学进展》2021年第9期820-824,共5页Advances in Cardiovascular Diseases

摘　　要：血脂异常,尤其是低密度脂蛋白胆固醇的升高,是冠状动脉粥样硬化性心脏病的主要危险因素之一。他汀类降脂药物因其多种副作用,不能完全满足临床的需要。前蛋白转化酶枯草溶菌素9抑制剂,通过抑制前蛋白转化酶枯草溶菌素9与低密度脂蛋白胆固醇受体的结合,降低血液中低密度脂蛋白胆固醇水平,从而有效地降低冠状动脉粥样硬化性心脏病事件的发生率,改善临床预后。Dyslipidemia,especially the rise of low-density lipoprotein cholesterol,is one of the main risk factor of coronary atherosclerotic heart disease.Traditional statins can't meet people's needs completely because of their various side effects.Proprotein convertase subtilisin/kexin type 9 inhibitor can effectively reduce the incidence of coronary atherosclerotic heart disease and improve the clinical prognosis by inhibiting the binding of proprotein convertase subtilisin/kexin type 9 to low-density lipoprotein receptor.

关 键 词：前蛋白转化酶枯草溶菌素9 低密度脂蛋白胆固醇 冠状动脉粥样硬化性心脏病 

分 类 号：R54[医药卫生—心血管疾病]